Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.70 |
| ▸ | EBP | Q15125 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7111316 | 0.93 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7105785 | 0.93 | ESR1 (0.67) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL3863139 | 0.92 | ESR1 (0.78) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL13897604 | 0.92 | ESR1 (0.78) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL11186217 | 0.91 | ESR1 (0.77) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7105763 | 0.90 | ESR1 (0.72) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL8578487 | 0.89 | ESR1 (0.65) | ESR1ESR2EBPSIGMAR1 | |
| Hydrochloric Acid SCHEMBL7153807 | 0.89 | ESR1 (0.71) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL3870510 | 0.89 | ESR1 (0.82) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL11185809 | 0.89 | ESR1 (0.82) | ESR1ESR2EBPSIGMAR1PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | ESR1 1044/4885ESR2 2130/4885EBP 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.